JPMorgan analyst Robbie Marcus downgraded Zimmer Biomet (ZBH) to Neutral from Overweight with a $100 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet Holdings: Hold Rating Amid Revenue Miss and Market Share Decline
- Zimmer Biomet Holdings: Mixed Q3 Performance and Narrowed Guidance Justify Hold Rating
- Zimmer Biomet Holdings: Strong Innovation Pipeline and Financial Health Justify Buy Rating Despite Recent Challenges
- Zimmer Biomet price target lowered to $110 from $118 at Stifel
- Zimmer Biomet price target lowered to $112 from $122 at BTIG